

'NICE and the AMR Challenge'

Carla Deakin – Associate Director, NICE Office for Market Access 25 January 2017

NICE AMR related activities

NG15 Antimicrobial Stewardship

'OUTPUTS'

Syndrome Specific Short Guidelines

Transformational AM Guidance (TA)

New AM
Evidence
Summaries

AMR
Diagnostics
MedTech Briefings

'INTERACTIONS'

NHSE/NICE Diagnostics Liaison Group NHSE AMR Diagnostics Subgroup Medicines
Optimisation
Initiatives

ESPAUR

PHE

DH

The Diagnostics Clinical and Cost Effectiveness Challenge

Complexity and variation in diagnostic and care pathways Alternates
i.e. more than 1
technology
posing the same
value proposition

Benefits typically result indirectly i.e. from treatments rather than directly from diagnostic procedures

Real world implementat uncertain

Rapid product evolution .i.e short product life cycles End to end clinical studies following patients from diagnosis through care to outcomes rarely available

Lower level of resources available in diagnostic 'sector'

'Accommodated' by NICE DAP Methods and Processes

But what about capturing the 'externalities/benefits' relating to AM stewardship?

AMR Diagnostics related MedTech Briefings

MedTech Briefings=Advice

Product Description
Place in Pathway
Evidence Summary

Alere Afinion CRP for Creactive protein testing in primary care QuikRead go for C-reactive protein testing in primary care

Xpert GBS test for the intrapartum detection of group B streptococcus

Xpert Carba-R to identify people carrying carbapenemase-producing organisms

BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis

AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis

'Multi-MIB' format being finalised with AMR Diagnostics in mind

https://www.nice.org.uk/guidance/published?type=mib